“…Recent attempts to mitigate mefloquine neurotoxicity, including efforts sponsored by the U.S. military to develop a human “safety test” ( Walter Reed Army Institute of Research, 2006 ) to identify individuals with idiosyncratic susceptibility, have thus far failed to yield satisfactory results. Notwithstanding recent confusion over the absolute configuration of the currently marketed drug ( Ding and Hall, 2013; Schützenmeister et al, 2013 ), randomized trials of enantiomeric mefloquine ( Knight et al, 2011 ), originally thought less likely to induce CNS effects owing to slightly lower average brain accumulation ( Baudry et al, 1997; Dow et al, 2011 ), have also demonstrated a propensity similar to the currently licensed racemic mixture to induce idiosyncratic “centrally mediated” symptoms of “dizziness” and difficulties in concentration ( Tansley et al, 2010 ).…”